Nicolas Droppelmann
Overview
Explore the profile of Nicolas Droppelmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olmos R, Dominguez J, Vargas-Salas S, Mosso L, Fardella C, Gonzalez G, et al.
Endocr Relat Cancer
. 2023 Sep;
30(11).
PMID: 37671897
Molecular testing contributes to improving the diagnosis of indeterminate thyroid nodules (ITNs). ThyroidPrint® is a ten-gene classifier aimed to rule out malignancy in ITN. Post-validation studies are necessary to determine...
2.
Olmos R, Munoz F, Donoso F, Lopez J, Bruera M, Ruiz-Esquide M, et al.
Arch Endocrinol Metab
. 2021 May;
64(5):542-547.
PMID: 34033294
Objective: Warthin-like papillary thyroid cancer (WL-PTC) is an uncommon variant of PTC, usually associated with lymphocytic thyroiditis. Scarce evidence suggests that WL-PTC has similar clinical presentation to classic PTC (C-PTC),...
3.
Zavala L, Barra M, Olmos R, Tuttle M, Gonzalez H, Droppelmann N, et al.
Arch Endocrinol Metab
. 2019 May;
63(3):293-299.
PMID: 31038590
Objective: Our objective was to evaluate the trend of antithyroglobulin antibodies (TgAb) during follow-up of patients with differentiated thyroid cancer (DTC) treated without RAI, as well as their role in...
4.
Martinez J, Vargas-Salas S, Gamboa S, Munoz E, Dominguez J, Leon A, et al.
Horm Cancer
. 2019 Mar;
10(2-3):97-106.
PMID: 30903583
The use of BRAFV600E and RET/PTC1 as biomarkers to guide the extent of surgery in patients with papillary thyroid cancer (PTC) remains controversial. We assessed the combined use of demographic...
5.
Dominguez J, Martinez M, Massardo J, Munoz S, Droppelmann N, Gonzalez H, et al.
Rev Med Chil
. 2018 Jul;
146(3):282-289.
PMID: 29999097
Background: Differentiated thyroid cancer (DTC) is generally associated with a favorable prognosis. Its treatment requires surgery, selective use of radioiodine and levothyroxine, and its intensity must be adjusted to the...
6.
Dominguez J, Nilo F, Martinez M, Massardo J, Munoz S, Contreras T, et al.
Arch Endocrinol Metab
. 2018 Apr;
62(1):6-13.
PMID: 29694628
Objective We aimed to describe the presentation of papillary microcarcinoma (PTMC) and identify the clinical and histological features associated with persistence/recurrence in a Latin American cohort. Subjects and methods Retrospective...
7.
Navarrete-Dechent C, Veness M, Droppelmann N, Uribe P
G Ital Dermatol Venereol
. 2018 Feb;
153(3):403-418.
PMID: 29485258
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and is usually associated with a favorable prognosis in most patients. However, a small minority of patients will...
8.
Urra S, Fischer M, Martinez J, Veliz L, Orellana P, Solar A, et al.
Oncotarget
. 2018 Feb;
9(2):2445-2467.
PMID: 29416784
Papillary thyroid cancer (PTC) is the most prevalent endocrine neoplasia. The increased incidence of PTC in patients with thyroiditis and the frequent immune infiltrate found in PTC suggest that inflammation...
9.
Dominguez J, Nilo F, Contreras T, Carmona R, Droppelmann N, Gonzalez H, et al.
J Ultrasound Med
. 2017 May;
36(11):2299-2307.
PMID: 28543974
Objectives: Follow-up of patients with low-risk differentiated thyroid cancer treated with total thyroidectomy and radioiodine requires neck sonography and thyroglobulin (Tg). The need to stimulate Tg is controversial. The goal...
10.
Rodriguez R, Parra A, Gonzalez S, Molgo M, Droppelmann N, Acevedo F, et al.
Rev Med Chil
. 2017 Apr;
144(11):1448-1458.
PMID: 28394962
Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years...